Endogenous cholecystokinin regulates growth of human cholangiocarcinoma

B. M. Evers, Guillermo Gomez, Courtney Townsend, S. Rajaraman, J. C. Thompson

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

Exogenous administration of cholecystokinin (CCK) or caerulein inhibits growth of SLU-132, a human cholangiocarcinoma that we have shown to possess receptors for CCK. Chronic administration of cholestyramine, a resin that binds bile salts, increases release of CCK and growth of the pancreas in guinea pigs. Feeding the bile salt, taurocholate, inhibits meal-stimulated release of CCK. The purpose of this study was to determine whether endogenous CCK affects growth of the human cholangiocarcinoma, SLU-132. We implanted SLU-132 subcutaneously into athymic nude mice. The bile salt pool was depleted by feeding 4% cholestyramine for 40 days, either alone or enriched with 0.5% taurocholate for 32 days. When the mice were killed, tumors and pancreas were removed. Cholestyramine significantly inhibited the growth of SLU-132 and stimulated growth of the normal pancreas. Feeding of taurocholate acted to stimulate tumor growth. These results demonstrate that endogenous levels of CCK regulate growth of this human cholangiocarcinoma. Our findings suggest that manipulation of levels of endogenous gut hormones may, in the future, play a role in management of patients with certain gastrointestinal cancers.

Original languageEnglish (US)
Pages (from-to)317-323
Number of pages7
JournalAnnals of Surgery
Volume210
Issue number3
StatePublished - 1989

    Fingerprint

ASJC Scopus subject areas

  • Surgery

Cite this

Evers, B. M., Gomez, G., Townsend, C., Rajaraman, S., & Thompson, J. C. (1989). Endogenous cholecystokinin regulates growth of human cholangiocarcinoma. Annals of Surgery, 210(3), 317-323.